Compassionate use of Biogen’s Spinraza in GaliciaOn Thursday, daily El País carried a lengthy story about a child in the Spanish region of Galicia who is being treated with Biogen’s Spinraza (nusinersen), which was imported from Germany because it is not yet available in Spain.
One dose of gene therapy prevents bleeding in haemophilia BA single intravenous infusion of a novel bioengineered gene therapy can prevent bleeding in patients with haemophilia B, daily ABC reported on Wednesday.
Roche's Herceptin facing biosimilar competitionRoche’s breast cancer drug Herceptin (trastuzumab) faces biosimilar competition following the approval of biosimilar versions by the U.S. Food and Drug Administration (FDA) and the European Commission, financial Cinco Días reported on Wednesday. (APMHE 55870, APMHE 55674).
Almost 3,000 companies have left CataloniaOn Wednesday, financial El Economista carried a story including the list of companies which have left Catalonia since the illegal independence referendum of October 1, including some pharmaceutical firms.
Pfizer denies 'spontaneous erections' linked to Viagra plantPfizer has called claims that its manufacturing plant in Ireland is causing “spontaneous erections” among the male population of a nearby village “an amusing myth” and has reiterated that its manufacturing processes are highly sophisticated and regulated, dailies El Español and El Diario reported on Thursday.
Sanofi’s dengue vaccine withdrawn from PhilippinesPhilippine drug agency FDA has ordered the withdrawal of Sanofi Pasteur’s dengue vaccine Dengvaxia, which has already been used to immunise 734,000 children in the country, daily El Mundo reports on Friday. (APMHE 55897)
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.